贝舒地尔专利布局对创新药研发的启示

Inspiration from the patent layout of belumosudil on research and development of innovative drugs

Rho相关卷曲螺旋激酶(Rho associated coiled-coil-containing protein kinase,ROCK)2抑制剂贝舒地尔上市与商业上的成功,意味着ROCK2靶点经受住了临床及市场的双重考验。此类经过临床检验且市场前景良好的靶点通常备受国内创新药企业的认可和追随,但国内ROCK2靶点的创新研发者寥寥。现对这一反常现象进行分析,认为贝舒地尔国内不完善的专利布局是国内创新药企业跟进少的一个重要原因,启示创新药研发中专利布局的重要作用。

The listing and commercial success of belumosudil,the Rho associated coiled-coil-containing protein kinase(ROCK)2 inhibitor,means that ROCK2 target has withstood both clinical trials and test of market.Such targets that have been clinically tested and have good market prospects are usually recognized and followed by domestic innovative drug companies.However,there are few domestic innovative researchers of ROCK2 targets.This paper analyzed this abnormal phenomenon,it was believed that the incomplete patent layout of belumosudil in China was an important reason for the lack of follow-up by domestic innovative pharmaceutical companies.It was also concluded that the patent layout played an important role in the research and development of innovative drugs.